Kalaris Therapeutics (KLRS) Preferred Stock Liabilities (2019 - 2024)
Kalaris Therapeutics (KLRS) posted quarterly Preferred Stock Liabilities of $46.0 million for Q4 2024, up 3.58% year-over-year from $44.4 million in Q1 2024, and little changed quarter-over-quarter from $46.0 million in Q3 2024.
Kalaris Therapeutics (KLRS) Preferred Stock Liabilities (2019 - 2024) Analysis & Trends
Kalaris Therapeutics' Preferred Stock Liabilities history runs 4 years deep, the most recent figure standing at $46.0 million for Q4 2024.
- In Q4 2024, Preferred Stock Liabilities rose 3.58% year-over-year to $46.0 million; the TTM figure through Dec 2024 stood at $46.0 million (up 3.58% YoY), while the FY2024 annual figure was $46.0 million, up 3.58% from the prior year.
- Preferred Stock Liabilities for Q4 2024 stood at $46.0 million, roughly flat from $46.0 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $120.9 million in Q2 2020, with the low at $44.4 million in Q4 2023.
- The 3-year median for Preferred Stock Liabilities is $46.0 million (2024), against an average of $57.4 million.
- The sharpest annual moves came in 2020 and 2024: Preferred Stock Liabilities changed 0.0% in 2020, then climbed 3.58% in 2024.
- Kalaris Therapeutics' Preferred Stock Liabilities stood at $120.9 million in 2020, then tumbled by 63.28% to $44.4 million in 2023, then gained by 3.58% to $46.0 million in 2024.
- Business Quant data shows KLRS's Preferred Stock Liabilities at $46.0 million in Q4 2024, $46.0 million in Q3 2024, and $46.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 46.00 Mn |
| Sep 30, 2024 | 46.00 Mn |
| Jun 30, 2024 | 46.00 Mn |
| Mar 31, 2024 | 46.00 Mn |
| Dec 31, 2023 | 44.41 Mn |
| Jun 30, 2020 | 120.92 Mn |
| Mar 31, 2020 | 52.20 Mn |
| Dec 31, 2019 | 52.20 Mn |
| Sep 30, 2019 | 120.92 Mn |
| Jun 30, 2019 | 120.92 Mn |